Specify a stock or a cryptocurrency in the search bar to get a summary
ProKidney Corp.
PROKProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina. Address: 2000 Frontis Plaza Blvd., Winston-Salem, NC, United States, 27103
Analytics
WallStreet Target Price
4.67 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures PROK
Dividend Analytics PROK
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History PROK
Stock Valuation PROK
Financials PROK
Results | 2019 | Dynamics |